Unusual route of buprenorphine administration: an alternative approach for bypassing adverse drug reactions

Publication date: Available online 18 January 2019Source: Current Therapeutic ResearchAuthor(s): Azadeh Nazari, Shahram Naderi Mazjin, Mansour ShamsipourAbstractTramadol abuse is a critical and growing health concern in Asia. In Iran, tramadol abuse arises most commonly as a result of self-medicating that leads to tramadol dependence. Buprenorphine, a partial agonist of mu opioid receptors approved for the treatment of tramadol dependence, is administered sublingually due to its extensive first-pass metabolism and resulting low oral bioavailability. A 50-year-old man presenting with tramadol dependence after self-medicating for chronic low back pain experienced adverse reactions to a minimal dosage (0.8 mg) of sublingual buprenorphine. He was treated successfully with a modified protocol comprised of swallowing sublingual tablets (0.2 mg/day initially, which increased to 0.2 mg every 12 hours during maintenance therapy). This unusual case suggests that swallowing buprenorphine sublingual tablets may prevent adverse effects and reduce the rate of treatment dropout.

Source: Current Therapeutic Research - January 18, 2019 Category: Drugs & Pharmacology Source Type: research